×
Join our live online event
How top hedge funds use news to make money
form the stock market & how ordinary people are
copying their strategies
Register now!
form the stock market & how ordinary people are
copying their strategies
No thanks
OMER – omeros corporation (US:NASDAQ)
DELAYED
$
| Volume Shares | |
| 1 Day Range | |
| Volume Ratio | |
| 52 Week High | |
| 52 Week Low |
| VWAP | |
| Today’s Volatility | |
| 20 Days Volatility | |
| Open | |
| Prior Close |
1D
5D
1M
3M
YTD
1Y
3Y
1 Day
OMER
SPY
QQQ
Swipe to see more
Main News & Impact Reports
Date
Time
Symbol
Headline
Impact
4/11
08:10 am
omer
Omeros Co. (NASDAQ: OMER) had its "buy" rating re-affirmed by analysts at D. Boral Capital. They now have a $36.00 price target on the stock.
High
Report
Omeros Co. (NASDAQ: OMER) had its "buy" rating re-affirmed by analysts at D. Boral Capital. They now have a $36.00 price target on the stock.
4/10
09:32 am
omer
Omeros Announces the Omeros Oncology Clinical Steering Committee for AML to Help Guide Omeros' Proprietary OncotoX-AML Clinical Program [Yahoo! Finance]
Medium
Report
Omeros Announces the Omeros Oncology Clinical Steering Committee for AML to Help Guide Omeros' Proprietary OncotoX-AML Clinical Program [Yahoo! Finance]
4/10
09:10 am
omer
Omeros Announces the Omeros Oncology Clinical Steering Committee for AML to Help Guide Omeros’ Proprietary OncotoX-AML Clinical Program
Medium
Report
Omeros Announces the Omeros Oncology Clinical Steering Committee for AML to Help Guide Omeros’ Proprietary OncotoX-AML Clinical Program
4/9
02:31 am
omer
Omeros Co. (NASDAQ: OMER) was downgraded by analysts at StockNews.com from a "hold" rating to a "sell" rating.
Medium
Report
Omeros Co. (NASDAQ: OMER) was downgraded by analysts at StockNews.com from a "hold" rating to a "sell" rating.
4/8
09:00 am
omer
Omeros Corporation To Introduce Its Proprietary T-CAT™ Program for the Treatment of Multidrug-Resistant Pathogens in Plenary Session at Upcoming European Congress on Infectious Diseases
Medium
Report
Omeros Corporation To Introduce Its Proprietary T-CAT™ Program for the Treatment of Multidrug-Resistant Pathogens in Plenary Session at Upcoming European Congress on Infectious Diseases
4/1
11:03 pm
omer
Omeros Co. (NASDAQ: OMER) was upgraded by analysts at StockNews.com from a "sell" rating to a "hold" rating.
Low
Report
Omeros Co. (NASDAQ: OMER) was upgraded by analysts at StockNews.com from a "sell" rating to a "hold" rating.
4/1
12:46 pm
omer
Omeros Co. (NASDAQ: OMER) had its "hold" rating re-affirmed by analysts at Needham & Company LLC.
Medium
Report
Omeros Co. (NASDAQ: OMER) had its "hold" rating re-affirmed by analysts at Needham & Company LLC.
4/1
08:00 am
omer
Omeros Co. (NASDAQ: OMER) had its "buy" rating re-affirmed by analysts at D. Boral Capital. They now have a $36.00 price target on the stock.
Medium
Report
Omeros Co. (NASDAQ: OMER) had its "buy" rating re-affirmed by analysts at D. Boral Capital. They now have a $36.00 price target on the stock.
Date
Time
Symbol
Company Name
Action
%Chg
Date
Time
Action
From
To
Firm
Impact
%Chg
Date
Time
Symbol
Headline
Impact
3/31
04:29 pm
omer
Form 10-K OMEROS CORP For: Dec 31
Medium
Report
Form 10-K OMEROS CORP For: Dec 31
3/31
04:25 pm
omer
Form 8-K OMEROS CORP For: Mar 31
Medium
Report
Form 8-K OMEROS CORP For: Mar 31
2/21
05:43 pm
omer
Form SCHEDULE 13G/A OMEROS CORP Filed by: INGALLS & SNYDER LLC
Medium
Report
Form SCHEDULE 13G/A OMEROS CORP Filed by: INGALLS & SNYDER LLC
2/20
09:15 am
omer
Form 8-K OMEROS CORP For: Feb 20
Medium
Report
Form 8-K OMEROS CORP For: Feb 20
Stock Stats
| News Stats | |
|---|---|
| All News | |
| News Wires | |
| Media Monitoring | |
| SEC Edgar Filings | |
| Upgrades | |
| Downgrades | |
| Initiated | |
| Reiterated | |
| Last Earnings | |
| Last Earnings EPS | |
| Next Earnings | |
| Order Stats |
|---|
| Sub-Penny |
|
|
| Odd lot |
|
|
| Avg. bid-ask spread |
|
|
| Avg. bid-ask size |
|
|
| Shares at ask/bid |
|
|
| Off exchange |
|
|
Main News & Impact Reports
TOP News Gainers
3/2
Omeros Corporation Reports Updated Results from Narsoplimab HSCT-TMA Clinical Trial and Highlights from Recent Clinical and CMC Meetings with FDA
55.4%
3/31 Omeros Co. (NASDAQ: OMER) was upgraded by analysts at Zacks Investment Research from a "hold" rating to a "buy" rating. They now have a $12.00 price target on the stock. 17.3%
5/10 Omeros Co. (NASDAQ: OMER) was downgraded by analysts at Zacks Investment Research from a "buy" rating to a "hold" rating. 13.6%
8/8 Q2/2019 6/30/2019 EPS -0.290 ZacksConsensus -0.450 ActVsEst 0.160 - Beat 11.9%
10/28 Omeros Corporation Initiates BLA Submission for Narsoplimab for the Treatment of HSCT-TMA 6.2%
8/5 Omeros Corporation to Announce Second Quarter 2019 Financial Results on August 8, 2019 6.0%
2/4 Omeros Co. (NASDAQ: OMER) was downgraded by analysts at BidaskClub from a "sell" rating to a "strong sell" rating. 4.9%
11/4 Omeros Corporation Announces Publication of Study Results on the Impact of OMIDRIA on Opioid Use and Pain 4.6%
11/19 Omeros Presents New GPR174 Immuno-oncology Data Today at the American Association for Cancer Research Conference in Boston 4.6%
8/12 Omeros Co. (NASDAQ: OMER) was given a new $32.00 price target on by analysts at Maxim Group. They now have a "buy" rating on the stock. 4.2%
3/31 Omeros Co. (NASDAQ: OMER) was upgraded by analysts at Zacks Investment Research from a "hold" rating to a "buy" rating. They now have a $12.00 price target on the stock. 17.3%
5/10 Omeros Co. (NASDAQ: OMER) was downgraded by analysts at Zacks Investment Research from a "buy" rating to a "hold" rating. 13.6%
8/8 Q2/2019 6/30/2019 EPS -0.290 ZacksConsensus -0.450 ActVsEst 0.160 - Beat 11.9%
10/28 Omeros Corporation Initiates BLA Submission for Narsoplimab for the Treatment of HSCT-TMA 6.2%
8/5 Omeros Corporation to Announce Second Quarter 2019 Financial Results on August 8, 2019 6.0%
2/4 Omeros Co. (NASDAQ: OMER) was downgraded by analysts at BidaskClub from a "sell" rating to a "strong sell" rating. 4.9%
11/4 Omeros Corporation Announces Publication of Study Results on the Impact of OMIDRIA on Opioid Use and Pain 4.6%
11/19 Omeros Presents New GPR174 Immuno-oncology Data Today at the American Association for Cancer Research Conference in Boston 4.6%
8/12 Omeros Co. (NASDAQ: OMER) was given a new $32.00 price target on by analysts at Maxim Group. They now have a "buy" rating on the stock. 4.2%
TOP News Decliners
12/4
Omeros Co. (NASDAQ: OMER) had its "hold" rating re-affirmed by analysts at Needham & Company LLC.
-12.8%
5/6 Omeros Corporation to Announce First Quarter 2019 Financial Results on May 9, 2019 -9.3%
3/10 Omeros Co. (NASDAQ: OMER) was upgraded by analysts at ValuEngine from a "hold" rating to a "buy" rating. -8.7%
1/17 Omeros Co. (NASDAQ: OMER) was upgraded by analysts at BidaskClub from a "strong sell" rating to a "sell" rating. -7.8%
5/23 Omeros (OMER) Presents At UBS Global Healthcare Conference - Slideshow [Seeking Alpha] -5.9%
3/6 Omeros Co. (NASDAQ: OMER) was upgraded by analysts at BidaskClub from a "sell" rating to a "hold" rating. -5.7%
3/12 Omeros Co. (NASDAQ: OMER) was downgraded by analysts at BidaskClub from a "hold" rating to a "sell" rating. -5.7%
10/30 Omeros Co. (NASDAQ: OMER) was downgraded by analysts at Zacks Investment Research from a "buy" rating to a "hold" rating. -5.4%
2/25 Omeros Co. (NASDAQ: OMER) was upgraded by analysts at BidaskClub from a "strong sell" rating to a "sell" rating. -5.3%
12/27 Omeros Co. (NASDAQ: OMER) was upgraded by analysts at BidaskClub from a "strong sell" rating to a "sell" rating. -4.7%
5/6 Omeros Corporation to Announce First Quarter 2019 Financial Results on May 9, 2019 -9.3%
3/10 Omeros Co. (NASDAQ: OMER) was upgraded by analysts at ValuEngine from a "hold" rating to a "buy" rating. -8.7%
1/17 Omeros Co. (NASDAQ: OMER) was upgraded by analysts at BidaskClub from a "strong sell" rating to a "sell" rating. -7.8%
5/23 Omeros (OMER) Presents At UBS Global Healthcare Conference - Slideshow [Seeking Alpha] -5.9%
3/6 Omeros Co. (NASDAQ: OMER) was upgraded by analysts at BidaskClub from a "sell" rating to a "hold" rating. -5.7%
3/12 Omeros Co. (NASDAQ: OMER) was downgraded by analysts at BidaskClub from a "hold" rating to a "sell" rating. -5.7%
10/30 Omeros Co. (NASDAQ: OMER) was downgraded by analysts at Zacks Investment Research from a "buy" rating to a "hold" rating. -5.4%
2/25 Omeros Co. (NASDAQ: OMER) was upgraded by analysts at BidaskClub from a "strong sell" rating to a "sell" rating. -5.3%
12/27 Omeros Co. (NASDAQ: OMER) was upgraded by analysts at BidaskClub from a "strong sell" rating to a "sell" rating. -4.7%
Don’t Miss Out On The Next BIG Stock Move
Never get left behind with our daily ‘Shakers & Movers’ newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our newsletter below: